IHP Therapeutics is applying Glycobiology to develop novel medicines. Glycobiology is an emerging field of research and drug development, with potential for treating multiple diseases.
IHP compounds are novel small molecule glycan therapeutics that inhibit selectin and complement activity. IHP’s lead compound, IHP-102, is a dual P-selectin and complement inhibitor, which targets diseases in hematology and oncology. IHP-102 has potential as a prodromal rescue therapeutic for sickle cell disease patients in vaso-occlusive crisis. This would address a critical treatment gap and empower patients in home or outpatient settings. In addition, IHP-102 is also using a targeted, biomarker driven approach to treat solid tumors, based on established role of P-selectin & complement in certain cancers. Beyond, IHP-102, IHP is utilizing its considerable expertise in glycobiology to create novel, second generation glycans.